Wearable Device for Prevention of Opioid-Induced Respiratory Depression, Hypoxemia and Death
Wearable Device for Prevention of Opioid-Induced Respiratory Depression, Hypoxemia and Death
批准号:
10012569
负责人:
Lloyd Olson
金额:
$34.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-06-15 至 2021-06-30
关键词:
Admission activityApneaArousalBloodBreathingCare given by nursesCessation of lifeCritical CareDataDetectionDevice DesignsDevicesDiagnosisDiscipline of NursingDropsEvaluationFDA approvedFrequenciesFutureHeart ArrestHome environmentHospitalsHumanHypoxemiaInterventionLettersLifeLow PrevalenceMedical DeviceMedicareMonitorMyocardial InfarctionMyocardial IschemiaNursesOperative Surgical ProceduresOpioidOutcome MeasureOverdoseOxygenPatientsPersonsPhasePhysiologic pulsePostoperative PeriodPreventionPulse OximetrySample SizeServicesStimulusTactileTimeVentilatory Depressionbaseinnovationinterestopioid mortalityopioid usepatient tolerabilityphase 2 studypost-marketpreventrespiratoryrisk benefit ratiosuccessusabilitywearable device
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Significance: Opioids kill 250 persons daily in the US, mostly by respiratory arrest.
Hypoxemia (low blood oxygen), typically precedes respiratory arrest. Timely
detection and correction of hypoxemia saves lives. The Oxalert EPO is a wearable
device designed to automatically restore breathing and reverse hypoxemia without
human intervention.
The Oxalert EPO (Enhanced Pulse Oximeter) is an FDA designated Breakthrough
Device, (...more effective diagnosis or treatment for a life-threatening condition... for
which no equivalent alternatives exist... in the best interests of patients.)24
The FDA recognizes our initial proposed Indication for Use in hospitalized post-
operative patients receiving opioids. We intend to confirm feasibility both in-hospital
and at home, in order to support a later FDA Indication for Use in patients at home
using opioids. The Center for Medicare and Medicare Services (CMS) will now
reimburse automatically for FDA-approved Breakthrough Devices.
Preliminary Data: Zornow showed that automatic arousal was superior to 1:1
nursing care.17 Sessler incidentally verified the "Arousal Effect" in a study of 1200
post-op in-patients.16
Specific Aims: AIM1) Prove feasibility of the Oxalert arousal device for restoring
breathing and reversing hypoxemia in post-operative patients receiving opioids.
AIM2) Determine statistical scalability needs for future Phase II study.
AIM3) Evaluate patient tolerance, nurse feedbacl and human factors/usability.
AIM4) Compare the extent of nocturnal oxygen desatuations in home-use before
and after surgery, with and without Oxalert interventions.
Summary: Breakthrough Device status should facilitate FDA approval for the
Oxalert EPO. Devices with a favorable Risk:Benefit ratio under the Twenty-First
Cures Act qualify for less FDA emphasis on lengthy pre-market studies as opposed
to post-market data in order to expedite patient access. We hope to find the
shortest path to getting this device to all who might benefit.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Wearable device for prevention of postoperative and post-discharge hypoxemia: A randomized pilot trial.
用于预防术后和出院后低氧血症的可穿戴设备:一项随机试点试验。
DOI:
10.1111/aas.14193
发表时间:
2023
期刊:
Acta anaesthesiologica Scandinavica
影响因子:
2.1
作者:
[Li,Kai, Saab,Remie, Bravo,Mauro, Mascha,EdwardJ, Han,Yanyan, Nault,Rod, Olson,Lloyd, Sessler,DanielI]
通讯作者:
Sessler,DanielI
海外基金